Norvir

Norvir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

In the first study of Norvir as an antiviral medicine, 16% of the Norvir-treated patients (86 out of 543) experienced a worsening of disease or died, compared with 33% of the patients taking placebo (181 out of 547). In the second study, patients taking Norvir had greater reductions in viral load and increases in CD4 cell counts than those taking zidovudine alone. The combination of Norvir and zidovudine was less effective than Norvir alone, although the reasons for this were unclear. Norvir, in combination with other antiviral medicines, also reduced viral loads in children.